• Mallinckrodt (NYSE: MNK) is exploring a sale
of its generic drug unit in a deal that could fetch as much as $ 2 billion, according to Reuters.
(Reuters)- Mallinckrodt Plc (MNK.N) is exploring a sale
of its generic drug unit, in a deal that could fetch as much as $ 2 billion and help pivot the specialty pharmaceutical maker toward higher - margin branded drugs, according to people familiar with the matter.
Not exact matches
Advisory panels to the Food and
Drug Administration (FDA) this week gave unanimous recommendations for so - called biosimilars
of Humira and Enbrel developed by Amgen and Novartis (nvs)
generics unit Sandoz, respectively.
Its Sandoz
unit was the first to win U.S. approval
of a «biosimilar»
drug — a treatment that's the cheaper
generic equivalent
of some
of the world's most expensive therapies.
Bain and Cinven, who earlier this year took control
of Germany's Stada, are hoping to use the Merck
unit as a buy - and - build platform for Stada, which makes
generic drugs and consumer care products and had annual revenues
of more than 2 billion euros in 2016, the sources said.